- Home
- SI vs OCGN Comparison
SI vs OCGN Comparison
Compare SI & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SI
- OCGN
- Stock Information
- Founded
- SI 2009
- OCGN 2013
- Country
- SI United States
- OCGN United States
- Employees
- SI N/A
- OCGN N/A
- Industry
- SI Medical/Dental Instruments
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SI Health Care
- OCGN Health Care
- Exchange
- SI Nasdaq
- OCGN Nasdaq
- Market Cap
- SI 257.1M
- OCGN 283.3M
- IPO Year
- SI 2025
- OCGN N/A
- Fundamental
- Price
- SI $15.63
- OCGN $1.06
- Analyst Decision
- SI Strong Buy
- OCGN Strong Buy
- Analyst Count
- SI 4
- OCGN 3
- Target Price
- SI $18.75
- OCGN $6.00
- AVG Volume (30 Days)
- SI 285.1K
- OCGN 2.2M
- Earning Date
- SI 01-17-2023
- OCGN 08-01-2025
- Dividend Yield
- SI N/A
- OCGN N/A
- EPS Growth
- SI N/A
- OCGN N/A
- EPS
- SI N/A
- OCGN N/A
- Revenue
- SI $34,571,000.00
- OCGN $4,754,000.00
- Revenue This Year
- SI N/A
- OCGN N/A
- Revenue Next Year
- SI N/A
- OCGN N/A
- P/E Ratio
- SI N/A
- OCGN N/A
- Revenue Growth
- SI 64.07
- OCGN N/A
- 52 Week Low
- SI $11.75
- OCGN $0.52
- 52 Week High
- SI $17.94
- OCGN $1.39
- Technical
- Relative Strength Index (RSI)
- SI N/A
- OCGN 55.75
- Support Level
- SI N/A
- OCGN $0.98
- Resistance Level
- SI N/A
- OCGN $1.07
- Average True Range (ATR)
- SI 0.00
- OCGN 0.04
- MACD
- SI 0.00
- OCGN 0.00
- Stochastic Oscillator
- SI 0.00
- OCGN 86.36
About SI Shoulder Innovations Inc. Common Stock
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").